ACM
KYTX icon

Accent Capital Management’s Kyverna Therapeutics KYTX Stock Holding History

Accent Capital Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.86K Hold
545
– – ﹤0.01% 285
2026
Q1 		$4.7K Buy
+545
New +$4.54K ﹤0.01% 288

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Accent Capital Management's KYTX Position: Q2 2026 in Review

Accent Capital Management held its Kyverna Therapeutics (KYTX) position steady in Q2 2026 at 545 shares worth $4.86K. The position accounts for ﹤0.01% of the portfolio, ranked #285.

Accent Capital Management first reported a position in KYTX in Q1 2026 and has held it in 2 quarters since. 121 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Accent Capital Management held 545 shares of Kyverna Therapeutics worth $4.86K as of Q2 2026.
  • Accent Capital Management left its Kyverna Therapeutics share count unchanged in Q2 2026.
  • Kyverna Therapeutics made up ﹤0.01% of Accent Capital Management's portfolio in Q2 2026, its #285 holding.
  • Accent Capital Management first reported a position in Kyverna Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 121 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Accent Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.